PH12018502155B1 - Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid - Google Patents

Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Info

Publication number: PH12018502155B1
Authority: PH; Philippines
Prior art keywords: antihypertensive; nsaid; beta blocker; pharmaceutical composition; converting enzyme
Prior art date: 2016-04-19

Application number

PH1/2018/502155A

Other languages

English (en)

Other versions

PH12018502155A1 (en

Inventor

Gilles Fonknechten

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-20

Filing date

2016-04-19

Publication date

2024-03-27

2016-04-19 Application filed by Servier Lab filed Critical Servier Lab

2019-07-15 Publication of PH12018502155A1 publication Critical patent/PH12018502155A1/en

2024-03-27 Publication of PH12018502155B1 publication Critical patent/PH12018502155B1/en

Links

239000002876 beta blocker Substances 0.000 title abstract 2
229940097320 beta blocking agent Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000005541 ACE inhibitor Substances 0.000 title 1
230000003276 anti-hypertensive effect Effects 0.000 title 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
239000002220 antihypertensive agent Substances 0.000 abstract 1
208000037849 arterial hypertension Diseases 0.000 abstract 1
229960002781 bisoprolol Drugs 0.000 abstract 1
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960002582 perindopril Drugs 0.000 abstract 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

PH1/2018/502155A 2016-04-20 2016-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid PH12018502155B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1653502A FR3050380B1 (fr)	2016-04-20	2016-04-20	Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
PCT/FR2017/050929 WO2017182754A1 (fr)	2016-04-20	2017-04-19	Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains

Publications (2)

Publication Number	Publication Date
PH12018502155A1 PH12018502155A1 (en)	2019-07-15
PH12018502155B1 true PH12018502155B1 (en)	2024-03-27

Family

ID=56943614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH1/2018/502155A PH12018502155B1 (en)	2016-04-20	2016-04-19	Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Country Status (15)

Country	Link
EP (1)	EP3445342A1 (fr)
KR (1)	KR102267965B1 (fr)
CN (1)	CN109069438A (fr)
BR (1)	BR112018070968A2 (fr)
EA (1)	EA201892354A1 (fr)
FR (1)	FR3050380B1 (fr)
GE (2)	GEP20217310B (fr)
MA (1)	MA44728A (fr)
MX (1)	MX389586B (fr)
PH (1)	PH12018502155B1 (fr)
RU (1)	RU2756320C2 (fr)
SG (2)	SG11201808848SA (fr)
TN (1)	TN2018000344A1 (fr)
UA (1)	UA125511C2 (fr)
WO (1)	WO2017182754A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2645710C2 (de)	1976-10-09	1985-06-27	Merck Patent Gmbh, 6100 Darmstadt	Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
FR2503155A2 (fr)	1980-10-02	1982-10-08	Science Union & Cie	Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620709B1 (fr)	1987-09-17	1990-09-07	Adir	Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2807431B1 (fr)	2000-04-06	2002-07-19	Adir	Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
GB2361185A (en) *	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
AR036187A1 (es)	2001-07-24	2004-08-18	Adir	Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
FR2827860B1 (fr)	2001-07-24	2004-12-10	Servier Lab	Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
ATE365714T1 (de)	2002-01-30	2007-07-15	Servier Lab	Verfahren zur herstellung von hochreinem perindopril und zwischenverbindungen nützlich in der synthese
FR2838648B1 (fr)	2002-04-18	2004-05-21	Servier Lab	Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
ATE395913T1 (de)	2003-02-28	2008-06-15	Servier S A Lab	Verfahren zur herstellung von perindopril
DE60301930T2 (de)	2003-02-28	2006-07-27	Les Laboratoires Servier	Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salze
PT1321471E (pt)	2003-03-12	2005-07-29	Servier Lab	Novo processo de sintese do perindopril e dos seus sais aceitaveis sob o ponto de vista farmaceutico
SI1367061T1 (sl)	2003-06-30	2006-04-30	Servier Lab	Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
SI1362864T1 (sl)	2003-06-30	2007-08-31	Servier Lab	Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
EP1648422A4 (fr) *	2003-07-28	2007-09-19	Reddys Lab Inc Dr	Traitement et prevention d'accidents cardiovasculaires
DK1367062T3 (da)	2003-07-31	2007-01-02	Servier Lab	Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
ES2271498T3 (es)	2003-07-31	2007-04-16	Les Laboratoires Servier	Nuevo procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
EP1380591B1 (fr)	2003-08-29	2005-11-16	Les Laboratoires Servier	Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
ES2250853T3 (es)	2003-08-29	2006-04-16	Les Laboratoires Servier	Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables.
DE60308102T2 (de)	2003-08-29	2007-06-21	Les Laboratoires Servier	Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salzen
DE60311942T2 (de)	2003-11-19	2007-12-06	Les Laboratoires Servier	Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen
EP1422236B1 (fr)	2003-11-19	2007-02-14	Les Laboratoires Servier	Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
SI1420029T1 (sl)	2003-12-10	2008-08-31	Servier Lab	Postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
SI21800A (sl)	2004-05-14	2005-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Nov postopek sinteze perindoprila
US20070116756A1 (en) *	2005-11-23	2007-05-24	Dr. Reddy's Laboratories Limited	Stable pharmaceutical compositions
FR2894825B1 (fr)	2005-12-21	2010-12-03	Servier Lab	Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2897866B1 (fr)	2006-02-28	2008-04-18	Servier Lab	Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2897865B1 (fr)	2006-02-28	2008-04-18	Servier Lab	Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN101024082A (zh) *	2007-04-06	2007-08-29	张士东	一种全面预防和治疗心脑血管疾病复方药及其应用
AU2009263737B2 (en)	2008-06-24	2013-10-24	Tianish Laboratories Private Limited	Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof
HU230877B1 (hu)	2008-09-30	2018-11-29	EGIS Gyógyszergyár NyR	Stabil kombinációs gyógyszerkészítmény
US9789187B2 (en) *	2009-02-11	2017-10-17	Cadila Pharmaceuticals Limited	Stable pharmaceutical composition for atherosclerosis
EP2424509A4 (fr) *	2009-04-30	2012-11-07	Reddys Lab Ltd Dr	Formulations de combinaison de médicament à dose fixe
FR2961105B1 (fr)	2010-06-15	2013-02-08	Servier Lab	Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
FR2985511B1 (fr)	2012-01-05	2014-01-03	Servier Lab	Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2016
- 2016-04-19 PH PH1/2018/502155A patent/PH12018502155B1/en unknown
- 2016-04-20 FR FR1653502A patent/FR3050380B1/fr not_active Expired - Fee Related
2017
- 2017-04-19 GE GEAP201714923A patent/GEP20217310B/en unknown
- 2017-04-19 CN CN201780023915.6A patent/CN109069438A/zh active Pending
- 2017-04-19 EA EA201892354A patent/EA201892354A1/ru unknown
- 2017-04-19 MX MX2018012790A patent/MX389586B/es unknown
- 2017-04-19 TN TNP/2018/000344A patent/TN2018000344A1/en unknown
- 2017-04-19 KR KR1020187033434A patent/KR102267965B1/ko not_active Expired - Fee Related
- 2017-04-19 BR BR112018070968A patent/BR112018070968A2/pt not_active Application Discontinuation
- 2017-04-19 GE GEAP202114923A patent/GEAP202114923A/en unknown
- 2017-04-19 RU RU2018140193A patent/RU2756320C2/ru active
- 2017-04-19 MA MA044728A patent/MA44728A/fr unknown
- 2017-04-19 SG SG11201808848SA patent/SG11201808848SA/en unknown
- 2017-04-19 UA UAA201811111A patent/UA125511C2/uk unknown
- 2017-04-19 WO PCT/FR2017/050929 patent/WO2017182754A1/fr not_active Ceased
- 2017-04-19 EP EP17722115.7A patent/EP3445342A1/fr not_active Withdrawn
- 2017-04-19 SG SG10202009894PA patent/SG10202009894PA/en unknown

Also Published As

Publication number	Publication date
SG11201808848SA (en)	2018-11-29
RU2018140193A3 (fr)	2020-06-03
PH12018502155A1 (en)	2019-07-15
FR3050380B1 (fr)	2020-07-10
FR3050380A1 (fr)	2017-10-27
MA44728A (fr)	2019-02-27
KR102267965B1 (ko)	2021-06-21
MX389586B (es)	2025-03-20
WO2017182754A1 (fr)	2017-10-26
GEAP202114923A (en)	2021-07-12
RU2018140193A (ru)	2020-05-20
KR20180132911A (ko)	2018-12-12
UA125511C2 (uk)	2022-04-13
TN2018000344A1 (en)	2020-06-15
EA201892354A1 (ru)	2019-04-30
BR112018070968A2 (pt)	2019-01-29
RU2756320C2 (ru)	2021-09-29
CN109069438A (zh)	2018-12-21
EP3445342A1 (fr)	2019-02-27
SG10202009894PA (en)	2020-11-27
GEP20217310B (en)	2021-11-10

Publication	Publication Date	Title
JOP20220008A1 (ar)	2023-01-30	مثبطات parp1
WO2016196776A3 (fr)	2017-01-05	Inhibiteurs de la tyrosine kinase de bruton
EP4335418A3 (fr)	2024-05-22	Compositions et méthodes pour le traitement du ptérygion
WO2016004305A3 (fr)	2016-03-03	Inhibiteurs de la tyrosine kinase de bruton
PH12019502782A1 (en)	2020-10-26	Fixed dose formulations
JOP20170105B1 (ar)	2022-03-15	مشتقات بيريدينيل تريازول مستبدلة بأميد واستخدامها
BR112016019592A8 (pt)	2018-01-02	Composto, uso de um composto, e, composição farmacêutica
CL2019002218A1 (es)	2020-02-21	Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
PH12020550462A1 (en)	2021-03-22	Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
EP4585213A3 (fr)	2025-10-08	Formulations d'amlodipine
IT201700025666A1 (it)	2018-09-08	Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
WO2018033941A3 (fr)	2018-04-05	Compositions pharmaceutiques à base d'ibrutinib
MX2020005344A (es)	2020-08-13	Compuestos de pirazolopiridinona.
WO2019043176A3 (fr)	2019-04-11	Inhibiteur de l'histone-désacétylase en association avec un agent antimétabolite pour la cancérothérapie
WO2012102560A3 (fr)	2012-10-18	Nouveau dérivé de 4-0-méthylhonokiol et composition contenant ce dérivé en tant que principe actif pour traiter des maladies inflammatoires
GB2549031A (en)	2017-10-04	Methods and drug therapies for patency of occluded blood vessels following angioplasty
CY1123322T1 (el)	2021-12-31	Φαρμακευτικη συνθεση περιλαμβανουσα μπισοπρολολη και περινδροπριλη
MX2020006905A (es)	2020-09-09	Composiciones farmaceuticas liquidas orales de aminosalicilatos.
TN2018000344A1 (en)	2020-06-15	Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
BR112013000532A2 (pt)	2016-06-07	composições farmacêuticas incluindo composto de carbamoilóxi arialcanoil arilpiperazina
MX2019013970A (es)	2020-02-10	Composiciones farmaceuticas de liberacion sostenida retardada.
PH12018500370A1 (en)	2018-08-29	Pharmaceutical composition comprising an hmg-coa reductase inhibitor and an ace inhibitor
MA44769B1 (fr)	2022-04-29	Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques
WO2019244014A3 (fr)	2020-02-13	Nouvelle utilisation d'inhibiteurs de monoamine oxydase de type b
PL384978A1 (pl)	2009-10-26	Zastosowanie ekstraktu z odtłuszczonych nasion wiesiołka